Longitudinal Detection of Circulating Tumor DNA in Children with Pleuropulmonary Blastoma: A Report from the International PPB/DICER1 Registry

PURPOSE: Pleuropulmonary blastoma (PPB) is the most common lung cancer of early childhood. Nearly all PPBs have biallelic DICER1 variants: a loss-of-function allele (often germline) and a second RNase IIIb domain "hotspot" substitution. Except in somatic mosaicism, these hotspots are tumor-specific and ideal liquid biopsy targets. EXPERIMENTAL DESIGN: For individuals with PPB enrolled in the International PPB/DICER1 Registry, blood samples were collected at timepoints coordinated with clinical venous access. Tumor sequencing identified each patient's RNase IIIb hotspot, enabling personalized droplet digital PCR assays to detect that variant in circulating tumor DNA (ctDNA). RESULTS: We analyzed 482 samples from 20 type I and 53 type II/III PPB patients. Among 13 pre-operative type II/III patients sampled pretreatment, 11 (85%) had detectable ctDNA, with tumor size moderately correlated with ctDNA burden (Spearman's ρ=0.574, p=0.051). In contrast, among 8 patients sampled after resection but before chemotherapy, none had detectable ctDNA (p<0.001 vs. unresected). After chemotherapy initiation, ctDNA levels spiked within 1-2 days before rapidly declining. During post-event surveillance, ctDNA was detectable a median of 5.3 weeks before clinical progression (21.7 weeks for negative samples; p=0.001). In type I PPB, DICER1 variants were detectable only in patients with somatic mosaicism. CONCLUSIONS: In type II/III PPB, ctDNA correlates with tumor size and resection status. The transient rise and fall in ctDNA following initiation of chemotherapy suggests that ctDNA could serve as a real-time in vivo assay of tumor responsiveness, and these findings support further investigation as a pharmacodynamic biomarker for disease response and recurrence detection.

Authors

Institutions

Publication Details

Journal
Clinical Cancer Research
Published
2026-11-17
DOI
https://doi.org/10.1158/1078-0432.ccr-26-1981
Primary Topic
Congenital Diaphragmatic Hernia Studies
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Longitudinal Detection of Circulating Tumor DNA in Children with Pleuropulmonary Blastoma: A Report from the International PPB/DICER1 Registry

Junne Kamihara, Brian D. Crompton, Anne K. Harris, David Brown Wilson et al.
2 links
Clinical Cancer Research
Congenital Diaphragmatic Hernia Studies
article

Longitudinal Detection of Circulating Tumor DNA in Children with Pleuropulmonary Blastoma: A Report from the International PPB/DICER1 Registry

Junne Kamihara, Brian D. Crompton, Anne K. Harris, David Brown Wilson, Sarah G. Mitchell, Alexander T. Nelson, Yan Su, Christina E. Amend, Benjamin Deonovic, Dana Ashley Hill, Kenneth Sung-Man Chen, Kris Ann P. Schultz, Chao Gao, Louis P. Dehner, Zhixia Yue, Kelly S. Klega, Kelly N. Hagedorn, DAVID A. WATSON, William A. Mize, Yoav H. Messinger, Damon R. Olson, Cuihai Duan, Paige H. R. Mallinger, Amanda L. Field, Chenyu Xu
article en

Abstract

PURPOSE: Pleuropulmonary blastoma (PPB) is the most common lung cancer of early childhood. Nearly all PPBs have biallelic DICER1 variants: a loss-of-function allele (often germline) and a second RNase IIIb domain "hotspot" substitution. Except in somatic mosaicism, these hotspots are tumor-specific and ideal liquid biopsy targets. EXPERIMENTAL DESIGN: For individuals with PPB enrolled in the International PPB/DICER1 Registry, blood samples were collected at timepoints coordinated with clinical venous access. Tumor sequencing identified each patient's RNase IIIb hotspot, enabling personalized droplet digital PCR assays to detect that variant in circulating tumor DNA (ctDNA). RESULTS: We analyzed 482 samples from 20 type I and 53 type II/III PPB patients. Among 13 pre-operative type II/III patients sampled pretreatment, 11 (85%) had detectable ctDNA, with tumor size moderately correlated with ctDNA burden (Spearman's ρ=0.574, p=0.051). In contrast, among 8 patients sampled after resection but before chemotherapy, none had detectable ctDNA (p<0.001 vs. unresected). After chemotherapy initiation, ctDNA levels spiked within 1-2 days before rapidly declining. During post-event surveillance, ctDNA was detectable a median of 5.3 weeks before clinical progression (21.7 weeks for negative samples; p=0.001). In type I PPB, DICER1 variants were detectable only in patients with somatic mosaicism. CONCLUSIONS: In type II/III PPB, ctDNA correlates with tumor size and resection status. The transient rise and fall in ctDNA following initiation of chemotherapy suggests that ctDNA could serve as a real-time in vivo assay of tumor responsiveness, and these findings support further investigation as a pharmacodynamic biomarker for disease response and recurrence detection.

Clinical Cancer Research
Mayo Clinic (US), Emory University (US), Washington University in St. Louis (US), Culture Resource (EG), Dana-Farber Cancer Institute (US), Mayo Clinic in Arizona (US), Children's Minnesota (US), University of Wisconsin American Family Children's Hospital (US), Care Resource (US), Beijing Children’s Hospital (CN), Mayo Clinic in Florida (US), Dana-Farber/Boston Children's Cancer and Blood Disorders Center (US), The University of Texas Southwestern Medical Center (US)
Good health and well-being
Congenital Diaphragmatic Hernia Studies
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon